fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Metabolic profiling

Written by | 13 Mar 2019

Metabolic interactions between the gut microbiome and its human host are thought to play a key role in the development of IBD and may hold the key to… read more.

VARSITY: head to head comparison of adalimumab vs vedolizumab in UC

Written by | 13 Mar 2019

The first-ever head-to-head comparative trial of two biological therapies in IBD indicates that UC patients treated with vedolizumab are significantly more likely to achieve remission than with adalimumab…. read more.

ECCO 2019 highlights

Written by | 11 Mar 2019

The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber… read more.

Highlights from ASH 2018

Written by | 14 Feb 2019

As usual, ASH provided lots of exciting updates in the management of lymphoma. One particularly interesting study from which data was presented at ASH was the ECHELON-2 study,… read more.

ASH 2018: Advances in the management of peripheral T-cell lymphoma

Written by | 5 Feb 2019

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphoid malignancies that often fails to respond to standard of care treatment,1-3 and the need for new therapies is… read more.

ASH 2018: Phoenix and other DLBCL study updates

Written by | 5 Feb 2019

Professor Anas Younes (New York, USA) and Dr Andrew Davies (Southampton, UK) discuss the outcomes from the Pheonix study, with Professor Anas Younes (New York, USA) highlighting future… read more.

Advanced stage disease

Written by | 5 Dec 2018

As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced… read more.

WCLC 2018: Variety of approaches can work in oligometastatic disease

Written by | 17 Oct 2018

Creative approaches that can be used to keep control of oligometastic disease in patients with non-small cell lung cancer were discussed here at the IASLC 19th World Conference on… read more.

WCLC 2018: Lung cancer stigma is detrimental to patient care

Written by | 17 Oct 2018

Dr Jesme Fox (Roy Castle Lung Cancer Foundation, UK) discusses research she presented showing that lung cancer stigma is detrimental to patients’ care.

WCLC 2018: Importance of QOL outcome measures in clinical trials

Written by | 17 Oct 2018

WCLC co-Presidents Professor Andrea Bezjak and Dr Natasha Leighl (both of Toronto, Canada) discuss research from their centre on the iimportance of QOL outcome measures in clinical trials.

WCLC 2018: Accessibility & quality of life: a patient focus at WCLC

Written by | 17 Oct 2018

Talk of progress in cancer treatment can ring hollow if the new, life-lengthening therapies are not widely available, the president-elect of the European Society of Medical Oncology said… read more.

WCLC 2018: PACIFIC: durvalumab results impressive, but not without questions

Written by | 17 Oct 2018

Patients with unresectable stage III non-small cell lung cancer taking durvalumab had significantly better overall survival than those on placebo after standard chemotherapy and radiation, according to the… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.